Cygnus Technologies is the leading provider of assays and services for the detection and characterization of impurities, such as host cell proteins, in biopharmaceuticals. Building on innovative, proprietary technology, the company develops highly specialized analytical products that meet the unique needs of the pharmaceutical, vaccine, gene therapy, and biotechnology industries.
Impurity analysis is an important step in biotherapeutic regulatory approval and quality control processes. With kits, immunoassay reagents, orthogonal analysis services, and expert advice, Cygnus Technologies helps biopharmaceutical companies accelerate the movement of new therapeutics through the development and approval stages to market.
Cygnus Technologies also offers outsourcing capabilities, using highly specialized technologies to develop custom, target-specific antibodies and assays. A privately held company, Cygnus Technologies was acquired by Maravai LifeSciences in 2016.